 MiMedx Group Inc NASDAQ: MDXG is trading significantly lower Monday after the company announced top-line results from two late-stage musculoskeletal clinical trials. Top-line results from an interim analysis of the six-month efficacy data for the Phase 2B clinical trial for Knee Osteoarthritis KOA did not meet primary endpoints, but revealed varied efficacy signals, prompting the company to plan for confirmatory efficacy studies for the KOA indication. 